CY1120436T1 - Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου - Google Patents
Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινουInfo
- Publication number
- CY1120436T1 CY1120436T1 CY20181100740T CY181100740T CY1120436T1 CY 1120436 T1 CY1120436 T1 CY 1120436T1 CY 20181100740 T CY20181100740 T CY 20181100740T CY 181100740 T CY181100740 T CY 181100740T CY 1120436 T1 CY1120436 T1 CY 1120436T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- androogenic
- cancer treatment
- pro
- lle
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89542407P | 2007-03-16 | 2007-03-16 | |
| PCT/EP2008/053127 WO2008113770A2 (en) | 2007-03-16 | 2008-03-14 | Anti-androgen peptides and uses thereof in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120436T1 true CY1120436T1 (el) | 2019-07-10 |
Family
ID=39766539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100740T CY1120436T1 (el) | 2007-03-16 | 2018-07-17 | Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100189776A1 (enExample) |
| EP (2) | EP3412685A1 (enExample) |
| JP (4) | JP5464344B2 (enExample) |
| AU (1) | AU2008228274B2 (enExample) |
| CY (1) | CY1120436T1 (enExample) |
| DK (1) | DK2139917T3 (enExample) |
| ES (1) | ES2677566T3 (enExample) |
| HR (1) | HRP20181178T1 (enExample) |
| HU (1) | HUE039249T2 (enExample) |
| LT (1) | LT2139917T (enExample) |
| PL (1) | PL2139917T3 (enExample) |
| PT (1) | PT2139917T (enExample) |
| SI (1) | SI2139917T1 (enExample) |
| TR (1) | TR201809422T4 (enExample) |
| WO (1) | WO2008113770A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100189776A1 (en) | 2007-03-16 | 2010-07-29 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
| GB2496135B (en) * | 2011-11-01 | 2015-03-18 | Valirx Plc | Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis |
| GB2513615A (en) * | 2013-05-01 | 2014-11-05 | Cancer Rec Tech Ltd | Medical use |
| WO2014188775A1 (ja) * | 2013-05-23 | 2014-11-27 | 国立大学法人東北大学 | アンドロゲンレセプター活性依存性乳癌細胞株の作製方法、当該細胞株を用いたスクリーニング方法、ならびに乳癌患者におけるアンドロゲンレセプター活性依存性獲得の判定方法、キット及びマーカー |
| KR102417496B1 (ko) * | 2019-11-29 | 2022-07-06 | (주)수파드엘릭사 | 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
| EP4157309A1 (en) | 2020-06-01 | 2023-04-05 | Black Cat Bio Limited | Compositions and methods for treating infections and netopathy |
| AU2023215340A1 (en) * | 2022-02-04 | 2024-09-19 | AecorBio Inc. | Medicinal uses of oligopeptides in combination with an antiandrogen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1005357A1 (en) * | 1997-04-14 | 2000-06-07 | The Regents Of The University Of California | Peptide antiestrogen compositions and methods for treating breast cancer |
| WO2000001813A2 (en) | 1998-06-30 | 2000-01-13 | The University Of British Columbia | Peptide inhibitors of androgen-independent activation of androgen receptor |
| WO2002060935A2 (en) * | 2000-12-21 | 2002-08-08 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| CA2446819A1 (en) * | 2001-05-08 | 2002-11-14 | Merck & Co., Inc. | Dna molecules encoding macaca mulatta androgen receptor |
| US7160989B2 (en) * | 2003-05-30 | 2007-01-09 | New York University | Antibodies that recognize and bind phosphorylated human androgen receptor and methods of using same |
| WO2007041497A2 (en) * | 2005-09-30 | 2007-04-12 | Cleveland Biolabs, Inc. | Modulation of androgen receptor |
| US20100189776A1 (en) * | 2007-03-16 | 2010-07-29 | Cancer Research Technology Ltd | Anti-androgen peptides and uses thereof in cancer therapy |
-
2008
- 2008-03-11 US US12/531,415 patent/US20100189776A1/en not_active Abandoned
- 2008-03-14 JP JP2009553162A patent/JP5464344B2/ja not_active Expired - Fee Related
- 2008-03-14 PL PL08717866T patent/PL2139917T3/pl unknown
- 2008-03-14 SI SI200831967T patent/SI2139917T1/sl unknown
- 2008-03-14 TR TR2018/09422T patent/TR201809422T4/tr unknown
- 2008-03-14 LT LTEP08717866.1T patent/LT2139917T/lt unknown
- 2008-03-14 DK DK08717866.1T patent/DK2139917T3/en active
- 2008-03-14 HR HRP20181178TT patent/HRP20181178T1/hr unknown
- 2008-03-14 PT PT87178661T patent/PT2139917T/pt unknown
- 2008-03-14 WO PCT/EP2008/053127 patent/WO2008113770A2/en not_active Ceased
- 2008-03-14 EP EP18155817.2A patent/EP3412685A1/en not_active Withdrawn
- 2008-03-14 HU HUE08717866A patent/HUE039249T2/hu unknown
- 2008-03-14 AU AU2008228274A patent/AU2008228274B2/en active Active
- 2008-03-14 ES ES08717866.1T patent/ES2677566T3/es active Active
- 2008-03-14 EP EP08717866.1A patent/EP2139917B1/en active Active
-
2014
- 2014-01-08 JP JP2014001333A patent/JP5998161B2/ja active Active
- 2014-12-18 US US14/575,065 patent/US9919023B2/en active Active
-
2016
- 2016-04-28 JP JP2016090783A patent/JP6545122B2/ja active Active
-
2018
- 2018-03-12 US US15/918,268 patent/US11560406B2/en active Active
- 2018-07-17 CY CY20181100740T patent/CY1120436T1/el unknown
-
2019
- 2019-04-02 JP JP2019070528A patent/JP6689430B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2139917T3 (en) | 2018-07-23 |
| LT2139917T (lt) | 2018-07-10 |
| US20180271933A1 (en) | 2018-09-27 |
| SI2139917T1 (sl) | 2018-10-30 |
| JP2014087363A (ja) | 2014-05-15 |
| TR201809422T4 (tr) | 2018-07-23 |
| ES2677566T3 (es) | 2018-08-03 |
| US11560406B2 (en) | 2023-01-24 |
| WO2008113770A2 (en) | 2008-09-25 |
| JP6545122B2 (ja) | 2019-07-17 |
| JP2010521441A (ja) | 2010-06-24 |
| EP2139917B1 (en) | 2018-04-25 |
| JP6689430B2 (ja) | 2020-04-28 |
| US20150202249A1 (en) | 2015-07-23 |
| AU2008228274B2 (en) | 2013-04-18 |
| US9919023B2 (en) | 2018-03-20 |
| PL2139917T3 (pl) | 2018-09-28 |
| AU2008228274A1 (en) | 2008-09-25 |
| JP2019150029A (ja) | 2019-09-12 |
| HUE039249T2 (hu) | 2018-12-28 |
| JP5998161B2 (ja) | 2016-09-28 |
| HRP20181178T1 (hr) | 2018-12-14 |
| PT2139917T (pt) | 2018-07-18 |
| EP2139917A2 (en) | 2010-01-06 |
| JP2016175927A (ja) | 2016-10-06 |
| WO2008113770A3 (en) | 2009-02-12 |
| US20100189776A1 (en) | 2010-07-29 |
| JP5464344B2 (ja) | 2014-04-09 |
| EP3412685A1 (en) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120436T1 (el) | Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| CY1122646T1 (el) | Δικυκλικες ετεροαρυλ ενωσεις | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1119265T1 (el) | Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου | |
| CY1118369T1 (el) | Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
| CY1119660T1 (el) | Antibakthpiakh απο toy στοματος συνθεση | |
| CY1113924T1 (el) | Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων | |
| CY1114272T1 (el) | Υποκατεστημενες διυδροπυραζολονες για την θεραπευτικη αντιμετωπιση των καρδιαγγειακων και αιματολογικων παθησεων | |
| UA117216C2 (uk) | Пухлиноасоційований пептид та його застосування | |
| EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| CY1117319T1 (el) | Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης | |
| CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1113282T1 (el) | Αντιικα νουκλεοζιτικα αναλογα | |
| CY1115836T1 (el) | Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων | |
| MA32161B1 (fr) | Formes de rifaximine et utilisations de celles-ci | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| CY1106476T1 (el) | Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες | |
| CY1112278T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους | |
| CY1110962T1 (el) | Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων | |
| CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 |